Actavis (ACT) said Friday a phase 3 study comparing dosage of its Dalvance for the treatment of acute bacterial skin and skin structure infections that are caused by susceptible Gram-positive bacteria reached both its primary and secondary endpoints. Preliminary data showed a single dose of 1500 mg Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy, as determined by a decrease of more than 20% in lesion area relative to the baseline measurement, the company said.
Actavis, Inc. (NYSE:ACT) shares closed the last trading session at 298.36. In the current trading session the stock reached as high as 298.33 and dipped down to 296.71. Actavis plc Ordinary Shares, a NYQ listed company, has a current market cap of 79.23B and on average over the past 3 months has seen 3310550 shares trade hands on a daily basis.
On a technical level the stock has a 50 Day Moving Average of 299.58. Based on a recent trade, this puts the equity at -0.66% away from that average. In looking at the 200-day average, the stock is +9.79% away from that mark. In comparing the stock’s current level to its extended history, the stock is trading -6.34% away from its 52-week high of 317.72 and +54.19% away from the stock’s low point over the past 52 weeks, which was 193.00.
There are a number of sell-side research brokerages which cover the stock and offer projections on earnings and future stock movement. On a consensus basis, analysts have a one year target price of 342.89. The company has a trailing 12-month EPS of -7.42. The consensus analyst estimates according to First Call for the next quarter is 4.42. The current year EPS estimate on the stock is 17.61 and the EPS estimate for next year sits at 21.28.
The price to earnings ratio, or the valuation ratio of a company’s current share price compared to its per-share earnings sits at N/A. This is an important indicator as a higher ratio typically suggests that investors are expecting higher future earnings growth compared to companies in the same industry with lower price to earnings ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 16.90. Potential shareholders looking further ahead, will note that the Price to next year’s EPS is 13.98.
This Little Known Stocks Could Turn Every $10,000 into $42,749!
Learn how you could trade stocks with 91% to 100% success rate by using this
revolutionary indicator that predicts when certain stocks are on the move.
You could be making up to 199% on a single trade in only 14 days.
